Abstract:Abstract Background Therapeutic lymphangiogenesis in an orthotopic lung transplant model has been shown to improve acute allograft rejection that is mediated at least in part through hyaluronan drainage. Lymphatic vessel endothelial hyaluronan receptor (LYVE-1) expressed on the surface of lymphatic endothelial cells plays important roles in hyaluronan uptake. The impact of current immunosuppressive therapies on lung lymphatic endothelial cells is largely unknown. We tested the hypothesis that FK506, the most commonly used immunosuppressant after lung transplantation, induces lung lymphatic endothelial cell dysfunction. Methods Lung lymphatic endothelial cells were cultured in vitro and treated with FK506. Telomerase activity was measured using the TRAP assay. Protein expression of LYVE-1 and senescence markers p21 and β-galactosidase was assessed with western blotting. Matrigel tubulation assay were used to investigate the effects of FK506 on TNF-α-induced lymphangiogenesis. Dual luciferase reporter assay was used to confirm NFAT-dependent transcriptional regulation of LYVE-1. Flow cytometry was used to examine the effects of FK506 on LYVE-1 in precision-cut-lung-slices ex vivo and on hyaluronan uptake in vitro . Results In vitro , FK506 downregulated telomerase reverse transcriptase expression, resulting in decreased telomerase activity and subsequent induction of p21 expression and cell senescence. Treatment with FK506 decreased LYVE-1 mRNA and protein levels and resulted in decreased LEC HA uptake. Similar result showing reduction of LYVE-1 expression when treated with FK506 was observed ex vivo . We identified a putative NFAT binding site on the LYVE-1 promoter and cloned this region of the promoter in a luciferase-based reporter construct. We showed that this NFAT binding site regulates LYVE-1 transcription, and mutation of this binding site blunted FK506-dependent downregulation of LYVE-1 promoter-dependent transcription. Finally, FK506-treated lymphatic endothelial cells show a blunted response to TNF-α-mediated lymphangiogenesis. Conclusion FK506 alters lymphatic endothelial cell molecular characteristics and causes lymphatic endothelial cell dysfunction in vitro and ex vivo. These effects of FK506 on lymphatic endothelial cell may impair the ability of the transplanted lung to drain hyaluronan macromolecules in vivo . The implications of our findings on the long-term health of lung allografts merit more investigation.

[Study on the Effect of Immunosuppressive Agent FK506 on Growth and Migration of Lung Cancer Cell].

Tacrolimus promotes hepatocellular carcinoma and enhances CXCR4/SDF‑1α expression in vivo.

Effects of FK506 on Cell Proliferation and Melanin Synthesis of Cultured Human Melanoma Cells

FK506 induces lung lymphatic endothelial cell senescence and downregulates LYVE-1 expression, with associated decreased hyaluronan uptake

EFFECT OF A NEW IMMUNOSUPPRESSIVE AGENT, FK506, ON HUMAN LYMPHOCYTE RESPONSES IN VITRO: I. Inhibition of Expression of Alloanticen‐Activated Suppressor Cells, As Well As Induction of Alloreactivity

FK506 promotes liver regeneration by suppressing natural killer cell activity

Acute Influence of FK506 on T-Lymphocyte Populations of Peripheral Blood and Spleen in Rats

Radiosensitizing effects of cyclooxygenase-2 selective inhibitor LM-1685 on A549 human lung adenocarcinoma cells

Overexpressed FKBP5 mediates colorectal cancer progression and sensitivity to FK506 treatment via the NF‐κB signaling pathway

FKBP51 Acts As a Biomarker of Early Metastasis and is Related to Carmustine Sensitivity in Human Glioma Cells.

[Effects of FK866 on Migration of A549 Cells and Related Mechanism].

Tacrolimus inhibits oral carcinogenesis through cell cycle control

FKBP12 is the only FK506 binding protein mediating T-cell inhibition by the immunosuppressant FK506

Tacrolimus inhibits NF-κB activity and lymphotactin gene expression after heart transplantation in mouse

Study on effect and mechanisms of IL-6 induced Gefitinib resistance in non-small cell lung cancer

Effects of Camp Interference on TNF-α Induced Rat Lung Fibroblast Proliferation

MicroRNA Expression Analysis During FK506-induced Osteogenic Differentiation in Rat Bone Marrow Stromal Cells

FKBP51 induces p53-dependent apoptosis and enhances drug sensitivity of human non-small-cell lung cancer cells.

Effect of a new immunosuppressive agent, FK506, on human lymphocyte responses in vitro. II. Inhibition of the production of IL-2 and gamma-IFN, but not B cell-stimulating factor 2.

[The study of FK506 eye drops preventing and treating immune rejection on limbal allograft transplantation]

Effect of Kaempferol on Tacrolimus-Induced Nephrotoxicity and Calcineurin B1 Expression Level in Animal Model